Remifentanil Without Muscle Relaxant for Thoracotomy
Primary Purpose
Elective Open Thoracotomy
Status
Completed
Phase
Phase 2
Locations
Saudi Arabia
Study Type
Interventional
Intervention
Muscle Relaxants (MR) group
Non- Muscle Relaxants (NMR) group
Sponsored by
About this trial
This is an interventional treatment trial for Elective Open Thoracotomy focused on measuring Thoracic surgery, non-muscle relaxant, target-controlled infusion, remifentanil, surgical conditions
Eligibility Criteria
Inclusion Criteria:
- American Society of Anesthesiologists physical class (II-III)
- elective open thoracotomy
Exclusion Criteria:
- New York Heart Association class> II)
- Forced vital capacity < 50% of the predicted values
- Forced expiratory volume in 1 second < 50% of the predicted values
- Hepatic diseases
- Renal diseases.
- Reactive airways.
- Neuromuscular diseases.
- Asthma
- Pregnancy
- Increased risk of regurgitation
- Anticipated difficult intubation
- Body mass index >35 kg/m2
- Electrolytes abnormalities
- Acid base abnormalities
- Repeat surgery
- history of head and neck surgery
- Preoperative circulatory support
- Preoperative ventilatory support
- Medications affecting the neuromuscular junctions
- Family history of malignant hyperthermia
- Allergy to any of the study drugs
Sites / Locations
- Dammam University
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Muscle Relaxants (MR) group
Non- Muscle Relaxants (NMR) group
Arm Description
Cisatracurium will be administered
No cisatracurium will be administered
Outcomes
Primary Outcome Measures
Modified surgical rating scale
A four-point ordinal scale adopted from the surgical rating scale of Martini et al.,ranging from 1 (extremely poor conditions) to 4 (optimal conditions).
Extremely poor (Score 1) indicates that the surgeon is unable to work because of coughing, bucking, diaphragmatic contractions or movements, or the inability to spread or approximate the ribs during chest opening and closure, respectively, because of inadequate muscle relaxation;
poor (Score 2) indicates that there is a visible field, but the surgeon is severely hampered by continuous muscle contractions, spontaneous movements of the surgical lung, or both that could cause hazard of tissue damage;
good (Score 3) indicates that there is an acceptable field with sporadic muscle contractions causing some interference with the surgeon's work;
excellent (Score 4) indicates a wide working field without any lung movement or muscle contractions.
Secondary Outcome Measures
heart rate
heart rate
Mean blood pressure
Mean blood pressure
Train-of-four ratio
Train-of-four ratio
laryngoscopy conditions
laryngoscopy conditions
intubating conditions
intubating conditions
Cost of medications
cost of the used medications
Need for vasoactive drugs
use of ephedrine, and norepinephrine
Recovery Times
the times to spontaneous eye opening, obey verbal command, tracheal extubation and post-anesthesia care unit discharge
Full Information
NCT ID
NCT02030808
First Posted
January 7, 2014
Last Updated
September 8, 2014
Sponsor
Imam Abdulrahman Bin Faisal University
1. Study Identification
Unique Protocol Identification Number
NCT02030808
Brief Title
Remifentanil Without Muscle Relaxant for Thoracotomy
Official Title
Target-Controlled Infusion of Remifentanil Without Muscle Relaxant Allows Acceptable Surgical Conditions During Thoracotomy
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
March 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imam Abdulrahman Bin Faisal University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Although the administration of muscle relaxation is essential standard of care for thoracic procedures, it could cause long-reversal times and postoperative residual curarization (PORC) increasing length of post-anesthesia care unit (PACU) stay and hospital costs. Sugammadex offers new perspectives to reduce the incidence of PORC. Unfortunately it is not available in many countries because of its significantly high cost. We hypothesized that the use of target-controlled remifentanil infusion (TCI) with the non-muscle relaxant (NMR) would be associated with comparable surgical conditions and reduced total costs compared with the use of neuromuscular blockers during thoracotomy.
After ethical approval, 66 patients scheduled for elective thoracotomy under sevoflurane anesthesia with TCI remifentanil will be included in this prospective, randomized, single-blind, controlled study.
Patients will be randomly assigned to receive cisatracurium or saline (n = 33 for each group) throughout the procedure. Laryngoscopy and intubating conditions, intraoperative modified thoracic surgery rating scale (Table below), incidence of light anesthesia, and use of vasopressors and anesthetics, clinical recovery, incidence of PORC, PACU and hospital stays, and total costs will be recorded.
Detailed Description
Administration of muscle relaxation is essential standard of care in thoracic surgery as it causes an improvement of surgical conditions. The concept of "Fast-track thoracic anesthesia" requires the use of either short or intermediate-acting nondepolarising neuromuscular blocking drugs, to provide a sufficient neuromuscular blockade during surgery and to restore the normal neuromuscular transmission immediately at the end of surgery.1
However, long-reversal times and postoperative residual curarization (PORC) are still a problem in 30%-60% of the anesthetized patients even with the use of new intermediate-acting neuromuscular blockers.2-3 PORC could cause aspiration of the lungs and respiratory failure4 after thoracic surgery that may prolong the post anesthesia care unit (PACU) and hospital stays.
Although, sugammadex, a modified gamma-cyclodextrin, offers new perspectives to reduce the incidence of PORC,4 it is not available in many countries because of its significantly high cost.5
Therefore, in fast-track cardiac surgery, it seems unnecessary to maintain paralysis by repetitive bolus injection or continuous infusion of neuromuscular blockers with overall surgeons' satisfaction.6
The use of remifentanil without muscle relaxants provides excellent intubating conditions and short recovery duration.7 The effective concentration range of remifentanil for tracheal intubation without muscle relaxant is 4.5-5.5 ng/ml.8 The use of non-muscle relaxant (NMR) anesthetic techniques using remifentanil with either propofol or sevoflurane allows early extubation after trans-sternal or video-assisted thymectomy in myasthenic patients.9-10
The use of NMR technique on the surgical conditions during thoracotomy in patients without neuromuscular diseases has not yet been studied.
We hypothesizes that the use of NMR technique during thoracotomy will be associated with comparable surgical conditions with the standard use of neuromuscular blockers.
The attending anesthesiologist is not blinded. All patients will be premedicated with 1-2 mg oral lorazepam the night before surgery.
In all patients, standard monitors, and state and response entropy (SE and RE, respectively) will be applied. Neuromuscular blockade is measured with a train-of-four (TOF) (Datex-Ohmeda Division, Instrumentarium Corporation, Helsinki, Finland). The forearm is immobilized to prevent interfering movements. The ulnar nerve will be stimulated supramaximally at the wrist with a TOF stimuli (60 mA for 200 μsec) at 15-sec intervals. Baseline twitch amplitude is established after induction of anesthesia. TOF ratio is recorded as ratio between the fourth and the first twitch (T4/T1).
The radial artery is catheterized. Normothermia is maintained by using forced-air warming blankets. A thoracic epidural or paravertebral catheter is inserted but no local anesthetics are infused during the study to avoid their effects on the study outcomes.
Anesthetic technique is standardized in all studied patients. Anesthesiologists who give the anesthetic will not be involved in the collection of outcome data.
After preoxygenation, anesthesia is induced using propofol 1.5-3 mg/kg and target-controlled infusion (TCI) of remifentanil at an effect-site concentration (Ce) of 4 ng/mL using the TCI system (Injectomat® TIVA Agilia, Fresenius Kabi, France), to achieve the SE values below 50 and the difference between RE and SE below 10 and the mean arterial blood pressure (MAP) and heart rate are <20% of the baseline values. When the SE is >50 and the RE-SE difference is >10, and the MAP and heart rate are >20%, propofol 0.5 mg/kg is administered followed with gradual increases in remifentanil Ce by 0.5 ng/mL with a maximum Ce of 6 ng/ml.
Anesthesia is maintained with 0.7-1.5 minimum alveolar concentration (MAC) of sevoflurane to maintain the SE values below 50 and the difference between RE and SE below 10.
Remifentanil Ce will be increased by 0.5 ng/mL when the SE values are > 50, the difference between RE and SE >10, and the MAP and heart rate are >20% of the baseline values despite a target sevoflurane MAC ≥ 1.5.
When the SE is <50 and the RE-SE difference is <10, the sevoflurane MAC will be gradually decreased to a minimum of 0.7, followed with gradual decreases in remifentanil Ce by 0.5 ng/mL with a minimum Ce of 1.5 ng/ml.
Light anesthesia is defined as an episode with SE values that exceeds 50 and/or MAP and HR values that exceeds the baseline by 20% and that lasted for more than 3 consecutive min.
Patients' two lungs (TLV) are mechanically ventilated with fraction of inspired oxygen (FiO2) of 0.4 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory (I: E) ratio of 1:2.5 and PEEP of 5 cm H2O, fresh gas flow (FGF) of 1.5-1.7 l/min, and respiratory rate adjusted to achieve a PaCO2 of 35-45 mm Hg.
After pleurotomy, the patient's dependent lung is ventilated with a TV of 6 mL/kg and FiO2, I: E ratio, PEEP, FGF, and respiratory rate, are maintained as during TLV and the lumen of the nondependent lung is left open to air.
Hemodynamic control is standardized according to the authors' protocol.
During surgery, the authors will administer Lactated Ringer's solution at a rate of 2 mL/kg/h. If MAP drops down to 60 mmHg, 250 mL of plasma protein fraction 5% will be administered, and, if this is not enough, repeated doses of intravenous of ephedrine 5 mg or norepinephrine 5 µg, will be administered to maintain urine output to be equal or greater than 0.5 ml/kg/hour. A hemoglobin concentration of 8 g/dL or greater is compensated with red blood cell concentrates.
All surgical procedures will be performed by the same surgeons who are blinded for the study.
In the case of clinically unacceptable laryngoscopy and intubating conditions, poor or extremely poor surgical conditions, or a sudden deterioration of surgical conditions despite the SE values below 50, the difference between RE and SE < 10, the MAP and heart rate are <20% of the baseline values, cisatracurium is administered in a bolus dose of 0.1 mg/kg.
At the end of surgery, the nondependent lung is re-expanded, TLV is resumed as before surgery. The remifentanil and sevoflurane will be discontinued after chest closure and skin closure (T0), respectively. In the Muscle Relaxant group, during skin closure, when the TOF ratio ranged between 0.3 and 0.5, the neuromuscular blockade is antagonized with 50 µg/kg neostigmine and 10 µg/kg glycopyrrolate.
Tracheal extubation will be performed immediately when all extubation criteria were achieved (TOF ratio ≥ 0.9, spontaneous ventilation, the ability to follow verbal commands, eyes opening, head lift ≥ 5 s, and hand grip).
A pilot study showed that the proportion of the surgeons who rated their satisfaction with surgical conditions as an excellent (Score 4) in anesthetized patients with cisatracurium was 92.5%. A priori power analysis indicated that a sample size of 30 patients was sufficiently large to detect a 30% difference in the proportion of the excellent operative conditions, during the use of NMRT, a type-I error of 0.05 and a power of 90%. We added more patients (10%) for a final sample size of 33 patients to compensate patients dropping out during the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Elective Open Thoracotomy
Keywords
Thoracic surgery, non-muscle relaxant, target-controlled infusion, remifentanil, surgical conditions
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
66 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Muscle Relaxants (MR) group
Arm Type
Placebo Comparator
Arm Description
Cisatracurium will be administered
Arm Title
Non- Muscle Relaxants (NMR) group
Arm Type
Active Comparator
Arm Description
No cisatracurium will be administered
Intervention Type
Drug
Intervention Name(s)
Muscle Relaxants (MR) group
Intervention Description
patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
Intervention Type
Drug
Intervention Name(s)
Non- Muscle Relaxants (NMR) group
Intervention Description
No cisatracurium® (Nimbex) will be administered
Primary Outcome Measure Information:
Title
Modified surgical rating scale
Description
A four-point ordinal scale adopted from the surgical rating scale of Martini et al.,ranging from 1 (extremely poor conditions) to 4 (optimal conditions).
Extremely poor (Score 1) indicates that the surgeon is unable to work because of coughing, bucking, diaphragmatic contractions or movements, or the inability to spread or approximate the ribs during chest opening and closure, respectively, because of inadequate muscle relaxation;
poor (Score 2) indicates that there is a visible field, but the surgeon is severely hampered by continuous muscle contractions, spontaneous movements of the surgical lung, or both that could cause hazard of tissue damage;
good (Score 3) indicates that there is an acceptable field with sporadic muscle contractions causing some interference with the surgeon's work;
excellent (Score 4) indicates a wide working field without any lung movement or muscle contractions.
Time Frame
for 3 hours after start of surgery
Secondary Outcome Measure Information:
Title
heart rate
Description
heart rate
Time Frame
5 min after induction of anesthesia, 1 min after chest opening, 30 min after start of surgery, 60 min after start of surgery, 90 min after start of surgery, 120 min after start of surgery, 1 min after start of chest closure, 5 min after extubation
Title
Mean blood pressure
Description
Mean blood pressure
Time Frame
5 min after induction of anesthesia, 1 min after chest opening, 30 min after start of surgery, 60 min after start of surgery, 90 min after start of surgery, 120 min after start of surgery, 1 min after start of chest closure, 5 min after extubation
Title
Train-of-four ratio
Description
Train-of-four ratio
Time Frame
5 min after induction of anesthesia, 1 min after chest opening, 30 min after start of surgery, 60 min after start of surgery, 90 min after start of surgery, 120 min after start of surgery, 1 min after start of chest closure, 5 min after extubation
Title
laryngoscopy conditions
Description
laryngoscopy conditions
Time Frame
1 min after laryngscopy
Title
intubating conditions
Description
intubating conditions
Time Frame
1 min after intubation
Title
Cost of medications
Description
cost of the used medications
Time Frame
after surgery
Title
Need for vasoactive drugs
Description
use of ephedrine, and norepinephrine
Time Frame
for 3 hour during surgery
Title
Recovery Times
Description
the times to spontaneous eye opening, obey verbal command, tracheal extubation and post-anesthesia care unit discharge
Time Frame
for 1 hours after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
American Society of Anesthesiologists physical class (II-III)
elective open thoracotomy
Exclusion Criteria:
New York Heart Association class> II)
Forced vital capacity < 50% of the predicted values
Forced expiratory volume in 1 second < 50% of the predicted values
Hepatic diseases
Renal diseases.
Reactive airways.
Neuromuscular diseases.
Asthma
Pregnancy
Increased risk of regurgitation
Anticipated difficult intubation
Body mass index >35 kg/m2
Electrolytes abnormalities
Acid base abnormalities
Repeat surgery
history of head and neck surgery
Preoperative circulatory support
Preoperative ventilatory support
Medications affecting the neuromuscular junctions
Family history of malignant hyperthermia
Allergy to any of the study drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohamed R El Tahan, MD
Organizational Affiliation
Associate Professor at Anesthesiology Dept
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mohamed A Regal, MD
Organizational Affiliation
Imam Abdulrahman Bin Faisal University
Official's Role
Study Chair
Facility Information:
Facility Name
Dammam University
City
Al Khubar
State/Province
Eastern
ZIP/Postal Code
31952
Country
Saudi Arabia
12. IPD Sharing Statement
Learn more about this trial
Remifentanil Without Muscle Relaxant for Thoracotomy
We'll reach out to this number within 24 hrs